Keros Therapeutics, Inc. (KROS)
Nasdaq · Healthcare · Biotechnology
$11.52+1.41%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $228M
- 52-week range
- $9.69 – $22.55
- 52-week change
- −27.27%
- EPS (trailing)
- −$3.22
- Analyst rating
- 1.9 Buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $244M
- Net income
- $87.0M
- Operating margin
- 27.7%
- Diluted EPS
- $2.30
- Free cash flow
- $106M
From the company’s annual report on SEC EDGAR.
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Headquarters: Lexington, United States · 92 employees · kerostx.com